CHG

522

+2.15%↑

CHG

522

+2.15%↑

CHG

522

+2.15%↑

CHG

522

+2.15%↑

CHG

522

+2.15%↑

Search

Halma PLC

Avatud

SektorTööstus

3,888 0.57

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3820

Max

3890

Põhinäitajad

By Trading Economics

Sissetulek

107M

187M

Müük

651M

1.2B

P/E

Sektori keskmine

39.217

47.787

Aktsiakasum

0.553

Dividenditootlus

0.67

Kasumimarginaal

15.096

Töötajad

9,000

EBITDA

184M

317M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-0.61% downside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.67%

2.01%

Turustatistika

By TradingEconomics

Turukapital

-166M

14B

Eelmine avamishind

3887.43

Eelmine sulgemishind

3888

Uudiste sentiment

By Acuity

34%

66%

95 / 406 Pingereas Industrials

Halma PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. veebr 2026, 23:21 UTC

Omandamised, ülevõtmised, äriostud

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15. veebr 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15. veebr 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15. veebr 2026, 23:06 UTC

Tulu

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15. veebr 2026, 23:04 UTC

Tulu

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15. veebr 2026, 23:04 UTC

Tulu

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15. veebr 2026, 23:01 UTC

Tulu

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15. veebr 2026, 23:01 UTC

Tulu

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15. veebr 2026, 22:52 UTC

Omandamised, ülevõtmised, äriostud

Qube Shareholders to Receive A$5.20/Share in Cash

15. veebr 2026, 22:52 UTC

Omandamised, ülevõtmised, äriostud

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO Tania Archibald Speaking on a Call With Media

15. veebr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15. veebr 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15. veebr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15. veebr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15. veebr 2026, 20:48 UTC

Tulu

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15. veebr 2026, 20:47 UTC

Tulu

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15. veebr 2026, 20:46 UTC

Tulu

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15. veebr 2026, 20:45 UTC

Tulu

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15. veebr 2026, 20:44 UTC

Tulu

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15. veebr 2026, 20:44 UTC

Tulu

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15. veebr 2026, 20:43 UTC

Tulu

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15. veebr 2026, 20:42 UTC

Tulu

BlueScope Net Debt A$2.2 Million at Dec. 31

15. veebr 2026, 20:42 UTC

Tulu

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15. veebr 2026, 20:41 UTC

Tulu

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15. veebr 2026, 20:40 UTC

Tulu

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15. veebr 2026, 20:40 UTC

Tulu

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15. veebr 2026, 20:39 UTC

Tulu

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Võrdlus sarnastega

Hinnamuutus

Halma PLC Prognoos

Hinnasiht

By TipRanks

-0.61% langus

12 kuu keskmine prognoos

Keskmine 3,852.31 GBX  -0.61%

Kõrge 4,280 GBX

Madal 2,490 GBX

Põhineb 13 Wall Streeti analüütiku instrumendi Halma PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

13 ratings

7

Osta

5

Hoia

1

Müü

Sentiment

By Acuity

95 / 406 Pingereas Tööstus

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Halma PLC

Halma plc, together its subsidiaries, provides technology solutions in the safety, health, and environmental markets in the United States, Mainland Europe, the United Kingdom, the Asia Pacific, Africa, the Middle East, and internationally. It operates through three segments: Safety, Environmental & Analysis, and Healthcare. The Safety segment provides products that protect people, assets and infrastructure, and electrical systems which is used in public and commercial spaces and in industrial and logistics operations. This segment serves Fire Safety, Power Safety, Industrial Safety, and Urban Safety markets. The Environmental & Analysis segment offers optical, optoelectronic, and spectral imaging systems; environmental monitoring; analysis of air quality, gases, and water; detection of hazardous gases; and water analysis & treatment systems. It serves the optical analysis, water analysis and treatment, and environmental monitoring markets. The Healthcare segment provides components, devices and systems that provide information and analytics to understand patient health and make decisions across the continuum of care; technologies and solutions to enable in-vitro diagnostic systems and life-science discoveries and development; and technologies that enable treatment across clinical specialties, as well as critical fluidic components used by medical diagnostics and original equipment manufacturers. This segment serves the life sciences, health assessment and analytics, and therapeutic solutions market. The company was incorporated in 1894 and is headquartered in Amersham, the United Kingdom.
help-icon Live chat